Daiichi Sankyo And Astrazeneca Enter New Global Development And Commercialization Collaboration For Daiichi Sankyos

Daiichi Sankyo And Astrazeneca Enter New Global Development And Commercialization Collaboration For Daiichi Sankyos

By, Admin 29 July 2020

Daiichi Sankyo Company, Limited Announced That It Has Entered Into A Global Development And Commercialization Agreement With Astrazeneca (Lse, Sto, Nyse: Azn) For Daiichi Sankyo&Rsquo;S Ds-1062, A Trop2 Directed Dxd Antibody Drug Conjugate (Adc), Currently In Phase 1 Clinical Development For Non-Small Cell Lung Cancer (Nsclc) And Triple Negative Breast Cancer (Tnbc).Daiichi Sankyo And Astrazeneca Will Jointly Develop And Commercialize Ds-1062 Worldwide, Except In Japan Where Daiichi Sankyo Will Maintain Exclusive Rights. Daiichi Sankyo Will Manufacture And Supply Ds-1062.This Agreement Represents The Second Global Adc Collaboration Between The Two Companies Following A Similar Agreement In March 2019 For Daiichi Sankyo&Rsquo;S Enhertu&Reg;, A Her2 Directed Dxd Adc.&Ldquo;Ds-1062, One Of Our Lead Dxd Adcs That Will Form A Pillar Of Our Next Mid-Term Business Plan, Has The Potential To Become A Best-In-Class Trop2 Adc In Multiple Tumors, Including Lung And Breast Cancers,&Rdquo; Said Sunao Manabe, Representative Director, President And Ceo Of Daiichi Sankyo Company, Limited. &Ldquo;This New Strategic Collaboration With Astrazeneca, A Company With Extensive Experience And Significant Expertise In The Global Oncology Business, Will Enable Us To Deliver Ds-1062 To More Patients Around The World As Quickly As Possible. As We Have Done With Enhertu, We Will Jointly Design And Implement Strategies To Maximize The Value Of Ds-1062.&Rdquo;&Ldquo;We See Significant Potential In This Antibody Drug Conjugate In Lung As Well As In Breast And Other Cancers That Commonly Express Trop2,&Rdquo; Said Pascal Soriot, Chief Executive Officer, Astrazeneca. &Ldquo;We Are Delighted To Enter This New Collaboration With Daiichi Sankyo And To Build On The Successful Launch Of Enhertu To Further Expand Our Pipeline And Leadership In Oncology. We Now Have Six Potential Blockbusters In Oncology With More To Come In Our Early And Late Pipelines.&Rdquo;

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!